Abbott Laboratories Ltd has decided to withdraw its European marketing authorisation application for Ozespa (briakinumab) which was intended to be used for moderate to severe chronic plaque psoriasis in adults, according to the EMA. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
